Correlation Engine 2.0
Clear Search sequence regions


  • adults (1)
  • asthma (5)
  • child preschool (1)
  • children (7)
  • face mask (1)
  • follow up studies (1)
  • humans (1)
  • infant (1)
  • japan (1)
  • salmeterol (4)
  • signals (1)
  • Sizes of these terms reflect their relevance to your search.

    Fluticasone propionate 50 μg/salmeterol xinafoate 25 μg (FP/SAL) is widely used in adults and children with asthma, but there is sparse information on its use in very young children. This was a randomized, double-blind, multicentre, controlled trial conducted in children aged 8 months to 4 years. During a 2-week run-in period, they all received FP twice daily. At randomization, they commenced FP/SAL or FP twice daily for 8 weeks. All were then given FP/SAL only, in a 16-week open-label study continuation. Medications were inhaled through an AeroChamber Plus with attached face mask. The primary end-point was mean change in total asthma symptom scores from baseline to the last 7 days of the double-blind period. Analyses were undertaken in all children randomized to treatment and who received at least one dose of study medication. Three hundred children were randomized 1:1 to receive FP/SAL or FP. Mean change from baseline in total asthma symptom scores was -3.97 for FP/SAL and -3.01 with FP. The between-group difference was not statistically significant (P = 0.21; 95% confidence interval: -2.47, 0.54). No new safety signals were seen with FP/SAL. This is the first randomized, double-blind study of this size to evaluate FP/SAL in very young children with asthma. FP/SAL did not show superior efficacy to FP; no clear add-on effect of SAL was demonstrated. No clinically significant differences in safety were noted with FP/SAL usage. © 2018 The Authors. Pediatric Allergy and Immunology Published by John Wiley & Sons Ltd.

    Citation

    Shigemi Yoshihara, Toshikazu Tsubaki, Masanori Ikeda, Warren Lenney, Richard Tomiak, Takako Hattori, Kenichi Hashimoto, Toru Soutome, Shihona Kato. The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2019 Mar;30(2):195-203

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 30556939

    View Full Text